Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for HIV protease inhibitors. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group common to all HIV protease inhibitors, e.g., saquinavir, nelfinavir, indinavir, amprenavir, ritonavir, lopinavir, and atazanavir.

Abstract: Toxin derivatives are prepared by proteolytic treatment of holotoxin, and their toxicity is reduced by contacting the preparation with a ligand, which can be a metal or an antibody or another ligand. This ligand selectively binds to the toxin but not to the toxin derivative. Removing the ligand and toxin bound to the ligand further reduces toxicity. A second ligand is used to remove conjugates of the toxin and the first ligand. Compositions contain the purified derivative, optionally plus the toxin and the ligand.

Abstract: Mono- and Bis-Azo/Hydrazone Pyrrole Pigments and Methods for preparing same.

Abstract: The invention provides a pyridone azo compound represented by the following Formula (I) R1, R3 and R4 each independently represent a hydrogen atom, an alkyl group having 1 to 21 carbon atoms, an alkenyl group having 2 to 21 carbon atoms, an aryl group having 6 to 21 carbon atoms, an aralkyl group having 7 to 21 carbon atoms, or a substituent having a hetero atom; at least one of R1, R3 and R4 represents a substituent having a hetero atom; R3 and R4 may be formed into a heterocycle together with a jointly bonded nitrogen atom; and R2 represents an alkyl group having 1 to 10 carbon atoms, a methoxymethyl group, or a trifluoromethyl group. The invention further provides a colorant-containing curable composition and a color filter which contain the pyridone azo compound of Formula (I) and/or a tautomer thereof as a colorant.

Abstract: Novel full-length cDNAs are provided. 2443 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

Abstract: Disclosed herein are isolated nucleic acid molecules encoding a humanized version of a calcitonin gene-related peptide (CGRP) receptor, which comprises the G-protein coupled receptor calcitonin-receptor-like receptor (CRLR) and the receptor-activity-modifying protein 1 (RAMP1). The humanized CGRP receptors of the present invention attain pharmacological profiles similar to the wild type human receptor via modifications to the respective mammalian RAMP1 nucleotide sequence, specifically at amino acid 74. Also described are related recombinant vectors, recombinant hosts and associated methods for generating such humanized CGRP receptors. Also presented are non-human transgenic animals which express humanized RAMP1. Such animals have been engineered to provide for a CGRP pharmacological profile similar to human CGRP.

Abstract: The present invention provides a DNA construct that confers tolerance to transgenic corn plant. Also provided are assays for detecting the presence of the PV-ZMGT32(nk603) corn event based on the DNA sequence of the recombinant construct inserted into the corn genome and of genomic sequences flanking the insertion site.

Abstract: The present invention provides non-invasive methods and compositions to differentiate, with a high level of sensitivity and specificity, swine that are genetically susceptible to diseases associated with F18 E. coli infection, from resistant swine. DNA polymorphisms in the swine alpha (1,2) fucosyltransferase 1 (FUT1) gene were used to differentiate resistant from susceptible swine. The invention includes a polypeptide with amino acid substitutions, encoded by the nucleotide polymorphisms, a molecular diagnostic assay, and a kit for the differentiation, of E. coli F18-adhesion resistant, heterozygous (carrier) and homozygous susceptible pigs. The molecular test identifies susceptibility to oedema disease and postweaning diarrhea with high sensitivity and specificity, therefore, is useful to swine breeder in their effort to enhance for resistance. Information on the polymorphisms of the present invention provides insight into causation and treatment of E. coli associated intestinal disorders.

Abstract: A novel polypeptide, a polynucleotide encoding this polypeptide, an expression vector comprising this polynucleotide, a cell transfected with the expression vector, an antibody binding to the above polypeptide, a convenient screening method for obtaining an agent for treating joint diseases, and a process for manufacturing a pharmaceutical composition for treating joint diseases are disclosed. The polypeptide is a novel aggrecanase causative of joint diseases (particularly an OA disease).

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention relates to novel promoter sequences derived from a portion upstream of the coding sequence of the gene for the CARP protein (Cardiac Ankyrin Repeat Protein), and which are capable of controlling the level and the specificity of expression of a transgene in vivo in cardiac muscle cells. The invention thus describes novel compositions, constructs, vectors and their uses in vivo for the transfer and expression of a nucleic acid in vivo in cardiac muscle cells. The subject of the present invention is also the use of the promoter sequences for generating transgenic animals which constitute models for studying certain cardiac pathologies.

Abstract: Disclosed herein is a novel gene which is isolated from Arabidopsis thaliana and shows senescence-specific expression. The expression of the gene is under the regulation of a promoter which is also disclosed herein. The gene in combination with the promoter can be utilized at the molecular level to control plant senescence in an environmentally friendly manner.

Abstract: Precursors for use in the synthesis of polynucleotides and methods of using the precursors in synthesizing polynucleotides are disclosed. The precursors include a heterocyclic base having an exocyclic amine group and a substituted or unsubstituted triaryl methyl protecting group bound to the exocyclic amine group.

Abstract: Disclosed herein is a process for production of an O-alkylrapamycin derivative represented by the general formula (1) below by reaction between rapamycin and alkyl triflate in an organic solvent, characterized in that the reaction is carried out in the presence of trialkylamine. (where R denotes alkyl, arylalkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, or aryl.) This process is capable of producing O-alkylrapamycin derivative efficiently owing to improvement in reaction yields for O-alkylation.

Abstract: The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-? (TNF-?). The chemically-synthesized indoloazepines of the invention also inhibit production of IL-2 and TNF-?. The indoloazepines are useful for treating inflammatory diseases, particularly diseases associated with kinases NF-?B or GSK-3? activation or NF-?B activated gene expression products. The indoloazepines are useful for the treatment of cancer by the inhibition of kinases CHK1 and CHK2.

Abstract: A dye-forming coupler and compound of formula (I): wherein Q represents a residue that forms, together with —N—C?N—, a nitrogen-containing 6-membered ring; RA represents an aryl, heterocyclic, or —(R1)r—(R4)m group; X represents an aryl group; Y represents a hydrogen atom, or a group capable of being split-off upon a coupling reaction with an oxidized product of a developing agent: wherein, when RA represents an —(R1)r—(R4)m group, R1 represents a methylene group, a methine group, or a carbon atom; r is 1 to 30; R4 represents a substituent except for a hydrogen atom; m is 1 to 30; and the —(R1)r—(R4)m group does not represent a straight-chain alkyl group.

Abstract: The method of preparing compounds of Formula I is described: wherein: M and V are cis to one another and MPO3H2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, and (R)-9-(2-phosphonylmethoxypropyl)adenine; wherein V is phenyl, optionally substituted with 1–2 substituents selected from a group consisting of fluoro, chloro, and bromo; comprising: coupling a chiral 1-phenylpropane-1,3-diol, wherein the phenyl may be optionally substituted, with MPOCl2 or an N-6 substituted analogue thereof. Additionally, methods and salt forms are described that enable isolation and purification of the desired isomer.

Abstract: New process for the production of (6S)-5,6,7,8-tetrahydrofolic acid or derivatives thereof starting from the corresponding (6S, 6R) racemic mixture. The procedure comprises in the steps of adding an organic acid to a non-alkaline suspension of (6S,6R)-5,6,7,8-tetraydrofolic acid, up to a pH value in the range of 1 to 3; heating the suspension from 30° to 80° C.; cooling the suspension from 20° to 60° C., with selective crystallization of the (6S)-isomer. The procedure gives the (6S)-isomer in high yields and with a high degree of stereoselectivity. It follows that the synthetic access to a large number of pharmacologically active stereoisomers of folic acid is simpler and more-effective.

Abstract: The invention provides a process for the preparation of a compound of the formula: or an acid addition or base salt thereof, wherein R is phenyl optionally substituted by 1 to 3 substituents each independently selected from halo and trifluoromethyl; R1 is C1–C6 alkyl; and “Het” is pyrimidinyl optionally substituted by 1 to 3 substituents each independently selected from C1–C4 alkyl, C1–C4 alkoxy, halo, oxo, benzyl and benzyloxy, comprising reaction of a compound of the formula: wherein R is as previously defined for a compound of the formula (I), with a compound of the formula: wherein R1 and “Het” are as previously defined for a compound of the formula (I) and X is chloro, bromo or iodo, in the presence of zinc, iodine and/or a Lewis acid and an aprotic organic solvent: said process being optionally followed by conversion of the compound of the formula (I) to an acid addition or base salt thereof.

Abstract: The present invention provides a polymorphic form of itraconazole.

Abstract: The invention relates to mixtures containing the dye C.I. Acid Red 82 (formula IIb) and C.I.

Abstract: A process for producing 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-carbaldehyde important as intermediate for the synthesis of pharmaceuticals, efficiently from an unnecessary antipode, is provided. A process for producing 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-carbaldehyde represented by the formula (III): which comprises treating a compound represented by the formula (I) or (II): (wherein A is —CHOH or —C(O)—, and R is a hydrogen atom, a C1-4 alkyl group which may be branched, a phenyl group, an alkali metal ion or an alkaline earth metal ion) with ozone, followed by reduction with an inorganic sulfur compound or by hydrogenation for reduction decomposition.

Abstract: A 4-aminopyridinium compound is represented by the formula (I) or (II). in which each of L1 and L3 is —O—CO—, —CO—O—, —C?C—, —CH?CH—, —CH?N—, —N?CH— or —N?N—; L2 is a single bond, —O—CO—, —CO—O—, —C?C—, —CH?CH—, —CH?N—, —N?CH— or —N?N—; m is 0 or 1; each of p and q is 1 to 10; each of R1 and R2 is an alkyl group or R1 and R2 are combined to form a ring; Z is cyano, an alkyl group, an alkoxy group, an acylalkyl group, an acylalkoxy group, an acyloxyalkyl group or an acyloxyalkoxy group; each of R3, R4 and R5 is a halogen atom; each of n1, n2 and n3 is 0 or 1; and X is an anion.

Abstract: Phosphorescent iridium complexes having Formula I or Formula II: wherein X is chosen from a monoanionic bidentate ligand; Z is chosen from an atomic group wherein Z together with the buta-1,3-diene to which Z is attached form an aryl group or heteroaryl group; R, R1, and R2 are independently chosen from a hydrogen atom or a substituent; m is an integer from 0 to 4; and n is an integer from 0 to the maximum number of possible substituents on Z, are disclosed. Light emitting devices using the phosphorescent iridium complexes are also disclosed.

Abstract: A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1?-methylbenzimidazol-2?-yl)benzimidazole with a compound of formula (IV) wherein Z is a leaving group, to obtain the compound 2-cyano-4?-[2?-n-propyl-4?-methyl-6?-(1??-methylbenzimidazol-2??-yl)benzimidazol-1?-ylmethyl]biphenyl, and subsequently hydrolyzing the nitrile function to obtain the acid function.

Abstract: A process for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, tert-butylester comprising: (a) reduction of 5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-oxo-1-pentanoic acid, (R)-2-hydroxy-1,2,2-triphenylethyl ester; (b) hydrolysis of (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (R)-2-hydroxy-1,2,2-triphenylethyl ester using an alkali base in a solvent to form the acid; (c) alkylation of the acid forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, tert-butylester.

Abstract: A process for coproducing alkyl-substituted or unsubstituted THF and pyrrolidones by catalytically hydrogenating C4-dicarboxylic acids and/or derivatives thereof in the gas phase in the presence of copper catalysts and reacting GBL with ammonia or primary amines to give pyrrolidones.

Abstract: The present invention relates to chiral diphosphorus compounds and their transition metal complexes, to a process for preparing chiral diphosphorus compounds and their transition metal complexes and also to their use in asymmetric syntheses.

Abstract: A process for preparing an alkylene oxide, which process comprises: (i) oxidizing an alkylbenzene to obtain a stream comprising alkylbenzene hydroperoxide, (ii) contacting at least part of the alkylbenzene hydroperoxide obtained in step (i) with an olefin to obtain a product stream comprising an alkylene oxide (iii) separating alkylene oxide compound from the product stream of step (ii) to obtain (a) a residual product stream comprising alkylphenyl alcohol, and (b) alkylene oxide, (iv) feeding at least a part of the residual product stream comprising alkylphenyl alcohol to a reactor having a catalytic distillation zone, and concurrently in the reactor, (a) contacting the residual product stream comprising alkylphenyl alcohol with hydrogen in the catalytic distillation zone to convert the alkylphenyl alcohol in the residual product stream to alkylbenzene and form a reaction mixture, and (b) separating alkylbenzene from the reaction mixture by fractional distillation, (v) withdrawing a stream comprising a

Abstract: A process for the epoxidation of an olefin, which process comprises reacting a feed comprising the olefin, oxygen and a reaction modifier in the presence of a highly selective silver-based catalyst at a reaction temperature T, and with the reaction modifier being present in a relative quantity Q which is the ratio of an effective molar quantity of active species of the reaction modifier present in the feed to an effective molar quantity of hydrocarbons present in the feed, and which process comprises the steps of: operating at a first operating phase wherein the value of T is T1 and the value of Q is Q1, and subsequently operating at a second operating phase at a reaction temperature which is different from the reaction temperature employed in the first operating phase, such that the value of T is T2 and the value of Q is substantially Q2, whereby Q2 is determined by calculation and Q2 is defined by the formula Q2=Q1+B(T2?T1), wherein B denotes a constant factor which is greater than 0; a reaction system

Abstract: A process for producing a conjugated di- or poly- unsaturated fatty acid having from 12 to 24 carbon atoms, or a salt or ester thereof, comprises reacting a non-conjugated free fatty acid, or a salt or ester thereof, with a base in the presence of a solvent comprising a monohydric alcohol having from 1 to 6 carbon atoms, wherein the reaction is carried out at a temperature of from 120° C. to 200° C. in the presence of water in an amount of at least 4% by weight based on alcohol.

Abstract: The present invention relates to a method of producing a fatty acid ester, including reacting fat and oil with an alcohol in the presence of at least one third component, wherein the third component is in a supercritical state or subcritical state under the condition of preventing a uniform phase from forming.

Abstract: A process for producing semiconductor nanocrystal cores, core-shell, core-buffer-shell, and multiple layer systems is disclosed. The process involves a non-coordinating solvent and in situ surfactant generation.

Abstract: The invention relates to a process for preparing racemic metallocene biphenoxide complexes by reacting bridged transition metal complexes with cyclopentadienyl derivatives of alkali metals or alkaline earth metals and heating the reaction mixture obtained in this way to a temperature in the range from ?78 to 250° C., to the corresponding metallocene biphenoxide complexes and to their use as catalysts or as constituents of catalysts for the polymerization of olefinically unsaturated compounds or as reagents or catalysts in stereoselective synthesis.

Abstract: Novel haloaluminoxane compositions have been formed. The halogen is fluorine, chlorine, and/or bromine, and the amount of halogen atoms present in said composition is in the range of about 0.5 mole % to about 15 mole % relative to aluminum atoms.

Abstract: A bromine/nitro moiety linked into the backbone of an ester or other compound over a wide range of occurrence rates provides antimicrobial, bio-resistant and fungal resistant properties for metal working fluids (MWF)s, coatings, plastics, and medical devices. The moiety can be have the bromo and nitro groups linked to the same or different carbon atoms. The present invention also relates to urethanes, urea, amides, imides, carbonates, ethers, siloxanes, and many other types of linkages essential to MWF bases.

Abstract: By means of a new process for the resolution of racemic 3-aminopentanenitrile, enantiomerically enriched 3-aminopentanenitrile or its salts can be obtained. For this, racemic 3-aminopentanenitrile is reacted with an enantiomerically enriched organic acid and one of the two diastereomeric salts formed is separated off and then converted into the enantiomerically enriched 3-aminopentanenitrile or its salts.

Abstract: Synthesis of N-[N-(3,3-dimethylbutyl)-L-?-aspartyl]-L-phenylalanine 1-methyl ester by treating N-(3,3-dimethylbutyl)-L-aspartic acid with ketones to give oxazolidinone derivatives, which are condensed with L-phenylalanine methyl ester.

Abstract: An aromatic polyester is pre-decomposed by heating together with bis-?-hydroxyethyl terephthalate and/or a low condensate thereof and then, reacted with ethylene glycol to convert the terephthalic acid component of the pre-decomposed product into bis-?-hydroxyethyl terephthalate and/or a low condensate thereof. The thus obtained solution composition, that is, bis-?-hydroxyethyl terephthalate solution composition containing ethylene glycol, bis-?-hydroxyethyl terephthalate and cations and/or anions as impurities is brought into contact with a cation exchanger and/or an anion exchanger to remove cations and anions as impurities to produce bis-?-hydroxyethyl terephthalate having a small content of ions.

Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, a trihalomethylcarbonyl group, such as a trifluoromethylcarbonyl group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.

Abstract: Provided are a novel halogenoacetoxyadamantane derivative which is useful as a modifying agent for a resin for a photoresist and a dry etching resistance-improving agent in the photolithography field, agricultural and medical intermediates and a compound for other various industrial products and a process for producing the same. To be specific, provided are a halogenoacetoxyadamantane derivative having a halogenoacetoxy group in an adamantane skeleton and a process for producing a halogenoacetoxyadamantane derivative, comprising the step of reacting a hydroxyl group of an adamantane skeleton with halogenoacetic halide or reacting the above hydroxyl group with a lithiation agent to derive it into a lithiumoxy group and then reacting halogenoacetic halide to introduce a halogenoacetoxy group.

Abstract: This invention relates to the use of a promoter in conjunction with a noble-metal-containing catalyst comprising a carbon support in catalyzing liquid phase oxidation reactions. In a particularly preferred embodiment, the catalyst comprises a carbon support having a noble metal and tellurium at a surface of the carbon support and is used in a liquid phase oxidation process wherein N-(phosphonomethyl)iminodiacetic acid (i.e., “PMIDA”) or a salt thereof is oxidized to form N-(phosphonomethyl)glycine (i.e., “glyphosate”) or a salt thereof.

Abstract: Specified phenylpropionic acid derivatives and analogues thereof have an antagonistic activity to ? 4 integrin. They are used as therapeutic agents or preventive agents for various diseases concerning ? 4 integrin, such as inflammatory diseases in which ? 4 integrin-depending adhesion process participates in the pathology, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

Abstract: The present invention relates to a process by which a carboxylic acid/diol mixture is obtained from a carboxylic acid/solvent slurry without isolation of a substantially dry carboxylic acid solid. More specifically, the present invention relates to a process by which a terephthalic acid/ethylene glycol mixture is obtained from a terephthalic acid/solvent slurry without isolation of a substantially dry terephthalic acid solid.